Hemodynamic and hormonal effects of beraprost sodium, an orally active prostacyclin analogue, in patients with secondary precapillary pulmonary hypertension
- PMID: 12736472
- DOI: 10.1253/circj.67.375
Hemodynamic and hormonal effects of beraprost sodium, an orally active prostacyclin analogue, in patients with secondary precapillary pulmonary hypertension
Abstract
Earlier studies have shown that administration of beraprost sodium (BPS), an orally active prostacyclin analogue, improves hemodynamics in patients with primary pulmonary hypertension (PH), but it is not known whether BPS has beneficial effects in secondary precapillary PH. The present study investigated the hemodynamic and hormonal parameters of 18 patients with secondary precapillary PH (8 patients with chronic thromboembolic PH, 7 with collagen vascular disease, and 3 with residual PH after surgery for atrial septal defect). Hemodynamics were repeatedly measured by right heart catheterization. Treatment with BPS improved New York Heart Association (NYHA) functional class in 10 of the 18 patients and significantly decreased pulmonary vascular resistance by 17% (12.9+/-1.1 to 10.7+/-1.2 Wood units, p<0.01). Circulating brain natriuretic peptide and uric acid significantly decreased from 246+/-61 to 215+/-65 pg/ml and from 6.5+/-0.6 to 5.3+/-0.3 mg/dl, respectively. In summary, BPS therapy improved NYHA functional class, hemodynamics, and hormonal parameters in patients with secondary precapillary PH. Thus, oral administration of BPS may be a new therapeutic strategy for the treatment of secondary precapillary PH.
Similar articles
-
[Effect of long-term therapy with oral Beraprost on survival of patients with arterial and inoperable thromboembolic pulmonary hypertension].Pol Arch Med Wewn. 2004 Apr;111(4):477-82. Pol Arch Med Wewn. 2004. PMID: 15517762 Polish.
-
Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction.Chest. 2003 May;123(5):1583-8. doi: 10.1378/chest.123.5.1583. Chest. 2003. PMID: 12740277 Clinical Trial.
-
Beneficial hemodynamic effects of oral prostacyclin (PGI2) analogue, beraprost sodium, on a patient with primary pulmonary hypertension--a case report.Angiology. 1998 Feb;49(2):161-4. doi: 10.1177/000331979804900210. Angiology. 1998. PMID: 9482517
-
Prostanoid therapy for pulmonary arterial hypertension.J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):56S-61S. doi: 10.1016/j.jacc.2004.02.036. J Am Coll Cardiol. 2004. PMID: 15194179 Review.
-
[Pharmacological and clinical properties of beraprost sodium, orally active prostacyclin analogue].Nihon Yakurigaku Zasshi. 2001 Feb;117(2):123-30. doi: 10.1254/fpj.117.123. Nihon Yakurigaku Zasshi. 2001. PMID: 11233303 Review. Japanese.
Cited by
-
Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline.Can Respir J. 2010 Nov-Dec;17(6):301-34. doi: 10.1155/2010/704258. Can Respir J. 2010. PMID: 21165353 Free PMC article.
-
Prostacyclin for pulmonary hypertension in adults.Cochrane Database Syst Rev. 2005 Apr 18;2005(2):CD002994. doi: 10.1002/14651858.CD002994.pub2. Cochrane Database Syst Rev. 2005. PMID: 15846646 Free PMC article.
-
Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease.Pediatr Cardiol. 2005 Nov-Dec;26(6):787-91. doi: 10.1007/s00246-005-0925-4. Pediatr Cardiol. 2005. PMID: 16132278
-
Drug treatment of pulmonary hypertension in children.Paediatr Drugs. 2014 Feb;16(1):43-65. doi: 10.1007/s40272-013-0052-2. Paediatr Drugs. 2014. PMID: 24114695 Free PMC article. Review.
-
Drug Treatment of Pulmonary Hypertension in Children.Paediatr Drugs. 2020 Apr;22(2):123-147. doi: 10.1007/s40272-019-00374-2. Paediatr Drugs. 2020. PMID: 31960361 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical